Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jse.2019.03.027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Consolidation With Second High Dose Therapy and Autologous Stem Cell Transplantation Is Associated With Improved Overall Survival in Patients With Multiple Myeloma in First Relapse.
Clin Lymphoma Myeloma Leuk
December 2024
Department of Hematology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Background: High dose chemotherapy and autologous stem cell transplantation (HDT/ASCT) remains the preferred first line consolidation strategy for newly diagnosed multiple myeloma (MM). However, The role of HDT/ASCT in first relapse is uncertain in the context of novel therapies. This study evaluates real-world outcomes of MM patients in first relapse, focusing on the role of consolidative HDT/ASCT.
View Article and Find Full Text PDFMaximizing expectancy violation and exposure outcomes in patients with PTSD.
Eur J Psychotraumatol
December 2025
Department of Clinical Psychology, Leiden University, Leiden, The Netherlands.
It has been proposed that maximizing expectancy violation enhances the efficacy of exposure therapy. The clinical utility of expectancy violation remains unclear and it has not yet been studied in PTSD. We aimed to test whether explicitly focusing on expectancy violation leads to superior exposure outcomes.
View Article and Find Full Text PDFG-quadruplex stabilization provokes DNA breaks in human PKD1, revealing a second hit mechanism for ADPKD.
Nat Commun
January 2025
Department of Biomedical Sciences, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI, USA.
The "secondhit" pathway is responsible for biallelic inactivation of many tumor suppressors, where a pathogenic germline allele is joined by somatic mutation of the remaining functional allele. The mechanisms are unresolved, but the human PKD1 tumor suppressor is a good experimental model for identifying the molecular determinants. Inactivation of PKD1 results in autosomal dominant polycystic kidney disease, a very common disorder characterized by the accumulation of fluid-filled cysts and end-stage renal disease.
View Article and Find Full Text PDFPGxDB: an interactive web-platform for pharmacogenomics research.
Nucleic Acids Res
January 2025
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, 2100 Copenhagen, Denmark.
Pharmacogenomics, the study of how an individual's genetic makeup influences their response to medications, is a rapidly evolving field with significant implications for personalized medicine. As researchers and healthcare professionals face challenges in exploring the intricate relationships between genetic profiles and therapeutic outcomes, the demand for effective and user-friendly tools to access and analyze genetic data related to drug responses continues to grow. To address these challenges, we have developed PGxDB, an interactive, web-based platform specifically designed for comprehensive pharmacogenomics research.
View Article and Find Full Text PDFClinical phenotyping uncovers heterogeneous associations between corticosteroid treatment and survival in critically ill COVID-19 patients.
Intensive Care Med
November 2024
Department of Intensive Care Medicine, Radboud university medical center, Nijmegen, The Netherlands.
Purpose: Disease heterogeneity in coronavirus disease 2019 (COVID-19) may render the current one-size-fits-all treatment approach suboptimal. We aimed to identify and immunologically characterize clinical phenotypes among critically ill COVID-19 patients, and to assess heterogeneity of corticosteroid treatment effect.
Methods: We applied consensus k-means clustering on 21 clinical parameters obtained within 24 h after admission to the intensive care unit (ICU) from 13,279 COVID-19 patients admitted to 82 Dutch ICUs from February 2020 to February 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!